key: cord-0846326-tjm9wyjz authors: Williams, Gregory P.; Muskat, Kaylin; Frazier, April; Xu, Yaqian; Mateus, José; Grifoni, Alba; da Silva Antunes, Ricardo; Weiskopf, Daniela; Amara, Amy W.; Standaert, David G.; Goldman, Jennifer G.; Litvan, Irene; Alcalay, Roy N.; Sulzer, David; Lindestam Arlehamn, Cecilia S.; Sette, Alessandro title: Unaltered T cell responses to common antigens in individuals with Parkinson’s disease date: 2022-04-08 journal: bioRxiv DOI: 10.1101/2022.04.05.487195 sha: 5a299ff2ccac41f4806bc736df3b88789976c2b7 doc_id: 846326 cord_uid: tjm9wyjz Background and Objectives Parkinson’s disease (PD) is associated with a heightened inflammatory state, including activated T cells. However, it is unclear whether these PD T cell responses are antigen specific or more indicative of generalized hyperresponsiveness. Our objective was to measure and compare antigen-specific T cell responses directed towards antigens derived from commonly encountered human pathogens/vaccines in patients with PD and age-matched healthy controls (HC). Methods Peripheral blood mononuclear cells (PBMCs) from 20 PD patients and 19 age-matched HCs were screened. Antigen specific T cell responses were measured by flow cytometry using a combination of the activation induced marker (AIM) assay and intracellular cytokine staining. Results Here we show that both PD patients and HCs show similar T cell activation levels to several antigens derived from commonly encountered human pathogens/vaccines in the general population. Similarly, we also observed no difference between HC and PD in the levels of CD4 and CD8 T cell derived cytokines produced in response to any of the common antigens tested. These antigens encompassed both viral (coronavirus, rhinovirus, respiratory syncytial virus, influenza, cytomegalovirus) and bacterial (pertussis, tetanus) targets. Conclusions These results suggest the T cell dysfunction observed in PD may not extend itself to abnormal responses to commonly encountered or vaccine-target antigens. Our study supports the notion that the targets of inflammatory T cell responses in PD may be more directed towards autoantigens like α-synuclein (α-syn) rather than common foreign antigens. Parkinson's disease (PD), the second most common neurodegenerative disease behind Alzheimer's disease (AD), affects over 6 million people globally. PD symptomology is typically characterized by motor dysfunction including bradykinesia, tremor, and rigidity. However, nonmotor symptoms often present long before clinical diagnosis and include loss of smell, disturbed sleep (e.g., REM sleep behavior disorder), constipation, and depression 1 . The major pathologies believed to underlie these PD symptoms are the degeneration of neurons (especially dopaminergic neurons in the substantia nigra) as well as the excessive accumulation and aggregation of the neuronal protein -synuclein (-syn) 2 . Alongside the hallmark neuronal pathology observed in PD is the observation of increased proinflammatory markers among several different cell types and spanning multiple tissues 3 . This includes both microgliosis and astrogliosis in the central nervous system (CNS) 4, 5 , as well as dysregulated monocyte populations in circulating blood 6, 7 . However, the heightened PD inflammatory state is not limited to innate immune cells; increased CD4 and CD8 T cell infiltration in PD postmortem brain and abnormal blood T cell frequencies, compared to healthy controls (HC), have also been observed in some studies [8] [9] [10] . More recent findings have expanded on the potential inflammatory nature of T cells in PD and shown that some PD patients have active -syn-specific T cell responses 11, 12 . A follow-up study showed that T cell responses in PD patients were associated with early PD and a longitudinal study of a single case showed that -syn-specific T cell responses were present years before the individual displayed symptoms 13 . Furthermore, the -syn evoked T cell responses reached their highest magnitude around the same time as that individual acquired a varicella-zoster virus (shingles) infection. Intriguingly, it has been observed that individuals on anti-TNF treatment are at a lower risk of developing PD 14 . It is, however, unclear whether these results are reflective of a general heightened inflammatory state and altered global immune function in PD, or more explicitly reflective of T cell responses specific to -syn and potentially other self-antigens. We set out to test whether there is a general increased T cell responsiveness in individuals with PD compared to age-matched HC. We utilized different cell-based assays to determine the magnitude, specificity, and type of T cell response to commonly encountered pathogen and vaccine antigens. These common antigens included common cold coronaviruses, rhinovirus, respiratory syncytial virus, influenza, cytomegalovirus, varicella-zoster virus, pertussis, and tetanus toxoid. Using the activation induced marker (AIM) assay [15] [16] [17] and intracellular cytokine staining (ICS) as a readout for T cell activation, we exposed both PD patient and age-matched HC peripheral blood mononuclear cells (PBMCs) to pathogen-specific peptide pools that have been previously shown to be targets of T cell responses. We found no difference in antigenspecific T cell activation between HC and individuals with PD. These results suggest that the inflammatory profile associated with PD does not influence the immune response to commonly encountered pathogens and vaccine targets. All participants provided written informed consent for participation in the study. Ethical approval was obtained from the Institutional Review Boards at La Jolla Institute for Immunology (LJI; Table 1 . Our lab routinely identifies CD4 and CD8 T cell epitopes, as well as uses existing data in the Immune Epitope Database and Analysis Resource (IEDB 18 ) to develop peptide "megapools". The utilization of "megapools" allows the ability to test a large number of epitopes spanning multiple HLA-types allowing a breadth of responses in immuno-diverse populations. Peptides were synthesized commercially as crude material by TC Peptide Lab (San Diego, CA). Lyophilized peptide products were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 20 mg/mL and their quality was spot checked by mass spectrometry. Overlapping and predicted class II peptides were combined to form antigen "pools" for all of the respective antigens tested. Composition of the peptide pools used in this study have been previously defined, characterized, and are listed in Table 2 . Note: Flu-Other references influenza antigens derived from flu proteins "other" than HA. PBMCs were thawed, washed, and counted for viability using the trypan blue exclusion method. A total of 1x10 6 For the intracellular cytokine assay, PBMCs were processed and stimulated in the same way as the AIM assay (described above), but with the following modifications: After the 24hr incubation Lymphocytes were analyzed using a standardized gating method (see Supplemental Fig. 1 for detailed gating strategy) used within the lab. On top of the previously described signal background subtraction in both AIM and ICS assays, another quality-control measure employed in this study was the exclusion of samples that did not have a ≥20% AIM/Cytokine + signal to the PHA-positive control stimuli. Statistical analyses were performed and graphs created using GraphPad Prism's descriptive statistics and two-tailed Mann Whitney tests. We utilized PBMCs from a cohort of age and sex-matched 19 HC and 20 PD individuals recruited from multiple sites (see Table 1 for detailed subject characteristics). PBMCs were stimulated with antigenic peptide pools specific for coronaviruses NL63, 229E, Table 2 for more detailed information on peptide pool compositions. Antigen pools tested were grouped into general classifications to aid in data viewing (e.g., Common Coronavirus, Lower Respiratory Tract Viruses). For CMV and EBV pools we also measured CD8-specific reactivity in addition to CD4 T cell responses (as these pools contain both class I and class II peptides). The antigen-specific T cell responses were measured using a flow cytometry activation-induced marker (AIM) assay [15] [16] [17] and antigen-specificity was determined as percentage of CD4 + cells expressing both OX40 + and CD137 +15,16 , or CD8 + cells expressing both CD69 + and CD137 +15,16 (Fig. 1a -d and Supplemental Fig. 1 for AIM gating strategy). No significant difference in the percentage of antigen-specific CD4 T cells between HC and PD was observed for any of the antigens tested. Similarly, we observed no difference in the CMV or EBV-specific CD8 AIM response between HC and PD (Fig 1e) . Additionally, we also measured the upregulation of other combinations of activation-associated markers and found no differences in responses between HC and PD (Supplemental Fig. 2) . As described above, we did not observe any significant differences between antigen-specific T cell activation in HC and PD individuals. To expand this observation, we next utilized a different assay system and addressed whether there is a difference in the specific cytokines produced between the two cohorts. PBMCs were stimulated with the same antigenic peptide pools used in the previous experiment and then the specific cytokine production was measured using an intracellular cytokine staining assay where we measured IFN, TNF, IL-2, IL-17a, IL-4, and IL-10 to represent the majority of Th subsets. In terms of Th1 associated cytokine responses, there was no statistical difference between HC and PD CD4 + , CD40L + , IFN producing T cells after stimulation with any of the antigen pools tested (Fig. 2a) . Some marginal reductions were seen for certain antigen/cytokine combinations, such as a lower CD4+ TNF-production in PD subjects in response to the 229E coronavirus and VZV antigen pool (Fig. 2b) , and reduced IL-2 production against the same common cold corona virus 229E antigen pool (Fig. 2c) . These decreases were however not significant after considering corrections for multiple comparisons (Bonferroni corrected critical value of 0.003). No detection or low levels of IL-4, IL-10, and IL-17a, along with CD8+ IFN or TNF were noted, with no difference in levels between HC and PD individuals (data not shown). Overall, we observed a generalized trend of lower cytokine responses in PD individuals and more specifically to the 229E common cold coronavirus strain, however these differences would not meet significance if corrected for multiple comparisons. Taken together, these results indicate that there is no difference between HC and PD in regard to antigen-specific T cell reactivity nor the types of cytokines produced to several commonly encountered antigens. However, the data presented here does not suggest an increased influenza-specific T cell response in PD patients compared to healthy controls. Another pathogen tested in this study, Epstein-Barr virus has previously been linked to PD [37] [38] [39] and EBV has been heavily implicated in development of another CNS disease, multiple sclerosis 40 . Lastly, it has been hypothesized that coronavirus infection may be involved in PD pathogenesis as increased CSF coronavirus antibodies have been previously been observed in PD patients 41 along with the fact that a coronavirus strain in mice was observed to infect and deteriorate their basal ganglia 42 . To our knowledge, this is the first study of its kind to measure antigen-specific T cell responses in patients with PD and HC to pathogens previously linked to PD (influenza, coronavirus, and EBV), as well as previously unassociated infectious species and vaccine antigens (rhinovirus, pertussis, and tetanus). In conclusion, though there are multiple reports detailing a baseline hyper-inflammatory state in PD, our results shown here suggest that this hyper-responsiveness does not apply to antigenspecific T cell responses to many commonly encountered antigens. Given the fact that there have been multiple associations with PD and infectious triggers, it may be that other facets of the immune system (auto-antibodies, bystander damage due to general inflammation) could be of more importance to these epidemiological connections than antigen-specific T cell responses. The only increased antigen-specific T cell response observed thus far in PD has been to -syn, a neuro-antigen. More work is needed in exploring if other relevant neuro-antigens might be the Parkinson's disease. Challenges in the diagnosis of Parkinson's disease Parkinson's disease. Lancet Innate and adaptive immune responses in Parkinson's disease Neurotoxic reactive astrocytes are induced by activated microglia Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease Alterations in Blood Monocyte Functions in Parkinson's Disease Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson's Disease Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. Neurol Neuroimmunol Neuroinflamm beta-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration T cells from patients with Parkinson's disease recognize alpha-synuclein peptides alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell A survey of known immune epitopes in the enteroviruses strains associated with acute flaccid myelitis IEDB-AR: immune epitope database-analysis resource in 2019 A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood Identification and Characterization of CD4(+) T Cell Epitopes after Shingrix Vaccination Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses CD4(+) T cells contribute to neurodegeneration in Lewy body dementia Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications The Demise of Poskanzer and Schwab's Influenza Theory on the Pathogenesis of Parkinson's Disease Association of Parkinson's disease with infections and occupational exposure to possible vectors Cohort Analysis of Parkinson's Syndrome: Evidence for a Single Etiology Related to Subclinical Infection About 1920 Parkinson's disease or Parkinson symptoms following seasonal influenza. Influenza Other Respir Viruses The role of T cells in age-related diseases Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus infection Human serum antibodies against EBV latent membrane protein 1 cross-react with alpha-synuclein Hypothesis: a role for EBVinduced molecular mimicry in Parkinson's disease Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease The authors want to sincerely thank all of the generous individuals who donated samples for the study. We are also grateful to the La Jolla Institute for Immunology's clinical core for processing the blood samples. The study is funded by the joint efforts of The Michael J. Fox Foundation for Parkinson's The authors report no relevant disclosures for this manuscript.